Less Grey Imaging

Less Grey Imaging是一家有前景的公司，旨在将先进的超声成像商业化为疾病诊断软件产品。该技术被称为超分辨率超声成像（SRUI），并提供了整个器官的微观细节图，这构成了器官结构和功能可视化的飞跃。虽然这项技术可用于诊断多种疾病，但我们已经确定前列腺癌是一种涉及大部分男性人口的主要疾病，因此构成了我们技术的巨大市场。我们的目的是创建一种软件形式的医疗器械/产品，作为现有诊断检查的辅助工具，以提供前列腺癌的准确诊断。这将有助于识别和定位目前在空间准确性上错过的重要癌症。此外，它还将有助于识别大量接受不必要活检或治疗的患者，从而降低医疗成本、患者风险和不便。我们受保护的创新不需要新硬件，并确保使用当前的超声设备生成前列腺的SRUI图，并在可行的患者检查时间（分钟）内生成。Less Grey软件最初可用于正确识别需要活检的患者，并提供患者监测和改善治疗计划。此外，我们设想将我们的技术应用于大量其他癌症和心血管疾病以及其他疾病。继Less Grey在ICURe项目期间取得成功并建议在Options Roundabout中分拆之后，Innovate UK资助的项目旨在通过提供清晰的商业计划，最终确定产品设计和临床使用，使Less Grey在一年内成为可投资项目。我们的计划是在四年内进入利润最丰厚的美国市场。为减低风险及减少与西方国家冗长的监管程序有关的成本，我们将以亚洲市场为首选。所采用的方向对超声技术非常有利，并将通过产生现金流在Less Grey的第一年提供公司稳定性。

Less Grey Imaging is a prospective company that aims to commercialise advanced ultrasound imaging into a software product for disease diagnosis. The technology is called super-resolution ultrasound imaging (SRUI) and provides maps of entire organs in microscopic detail, which constitutes a leap in the visualisation of the structure and function of organs. While this technology can be used for the diagnosis of several diseases, we have identified that prostate cancer is a major disease that concerns a large part of the male population, and thus constitutes a large market for our technology. Our intention is to create a medical device/product in the form of software that will work as an adjunct to existing diagnostic examinations to provide accurate diagnosis of prostate cancer. This will help identify & localise significant cancers that are currently missed with spatial accuracy. In addition, it will help identify the large number of patients that undergo unnecessary biopsy or treatment, thus reducing healthcare costs, patient risk, and inconvenience.Our protected innovation does not require new hardware and ensures that the SRUI maps of the prostate are generated with current ultrasound equipment, and within feasible patient examination times (minutes). The Less Grey software can be used initially to identify correctly patient in need of biopsy and additionally provide patient surveillance and enable improved treatment planning. Further, we envision the application of our technology to a large number of other cancers and cardiovascular disease as well as other diseases.Following Less Grey's success during the ICURe programme with the recommendation to spin out at the Options Roundabout, the Innovate UK funded project is designed to make Less Grey investable within one year, by providing a clear business plan, finalising product design and clinical usage. Our plan is to enter the most lucrative USA market within four years. To mitigate the risk and reduce the costs associated with the lengthy regulatory procedures in the western countries, we will engage with an Asian market as a first choice. The adopted direction is highly favourable for ultrasound technologies and will provide company stability during the first years of Less Grey by generating cash flow.